Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation
- PMID: 8226281
- PMCID: PMC5919057
- DOI: 10.1111/j.1349-7006.1993.tb02802.x
Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation
Abstract
In this study, we examined the effect of triflavin, an Arg-Gly-Asp (RGD)-containing snake venom peptide, on human cervical carcinoma (HeLa) cell- and B16-F10 mouse melanoma cell-induced platelet aggregation (TCIPA) in heparinized platelet-rich plasma. TCIPA appears to play an important role in the development of certain experimental tumor metastases. Two ADP-scavenging agents, apyrase (10 U/ml) and creatine phosphate (CP) (5 mM)/creatine phosphokinase (CPK) (5 U/ml) completely inhibited B16-F10 TCIPA, but hirudin (5 U/ml) had no effect. In contrast, apyrase and CP/CPK did not inhibit HeLa TCIPA while hirudin completely inhibited it. Furthermore, HeLa cells initially induced platelet aggregation and then blood coagulation at a later stage. In addition, HeLa cells shortened, in a concentration-dependent manner, the recalcification time of normal as well as factor VIII- and IX-deficient human plasma, but did not affect the recalcification time of factor VII-deficient plasma. This suggests that HeLa TCIPA occurs via activation of the extrinsic pathway, probably owing to tumor cell expression of tissue factor-like activity. HeLa cell-induced thrombin generation was confirmed by detection of amidolytic activity towards a chromogenic substrate, S-2238 (H-D-Phe-Pip-Arg-p-NA). Triflavin and GRGDS inhibited, in a dose-dependent manner, TCIPA caused by either cell line. On a molar basis, triflavin was 10,000-30,000 times more potent than GRGDS in this regard. Moreover, monoclonal antibodies raised against glycoprotein (GP) IIb/IIIa complex (i.e., 7E3 and AP2) and against GP Ib (i.e., AP1) completely inhibited HeLa TCIPA. 7E3 and AP2 inhibited B16-F10 TCIPA by up to 80% whereas AP1 showed only 30% inhibition of B16-F10 TCIPA. In conclusion, the inhibitory effect of triflavin on HeLa and B16-F10 TCIPA may be mediated principally by the binding of triflavin to the fibrinogen receptor associated with GP IIb/IIIa complex on the platelet surface. However, GP Ib is also involved in HeLa TCIPA as thrombin formation is the key factor in triggering platelet aggregation caused by HeLa cells.
Similar articles
-
Triflavin, an Arg-Gly-Asp containing snake venom peptide, inhibits aggregation of human platelets induced by human hepatoma cell line.Thromb Res. 1992 Jun 15;66(6):679-91. doi: 10.1016/0049-3848(92)90044-b. Thromb Res. 1992. PMID: 1519227
-
The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells.Br J Cancer. 1995 Feb;71(2):265-70. doi: 10.1038/bjc.1995.54. Br J Cancer. 1995. PMID: 7841039 Free PMC article.
-
Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.Breast Cancer Res Treat. 1995 Mar;33(3):225-35. doi: 10.1007/BF00665947. Breast Cancer Res Treat. 1995. PMID: 7749150
-
[Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation].Usp Fiziol Nauk. 1999 Apr-Jun;30(2):80-91. Usp Fiziol Nauk. 1999. PMID: 10420478 Review. Russian.
-
Novel antithrombotic drugs in development.Drugs. 1995 Jun;49(6):856-84. doi: 10.2165/00003495-199549060-00002. Drugs. 1995. PMID: 7641602 Review.
Cited by
-
Platelet Integrins in Tumor Metastasis: Do They Represent a Therapeutic Target?Cancers (Basel). 2017 Sep 28;9(10):133. doi: 10.3390/cancers9100133. Cancers (Basel). 2017. PMID: 28956830 Free PMC article. Review.
-
Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?Cancer Metastasis Rev. 2017 Jun;36(2):305-329. doi: 10.1007/s10555-017-9683-z. Cancer Metastasis Rev. 2017. PMID: 28752248 Free PMC article.
References
-
- Karpatkin , S. and Pearlstein , E.Role of platelets in tumor cell metastasis . Ann. Int. Med. , 95 , 636 – 641 ( 1981. ). - PubMed
-
- Gasic , G. J.Role of plasma, platelets and endothelial cells in tumor metastasis . Cancer Metastasis Rev. , 3 , 99 – 116 ( 1984. ). - PubMed
-
- Crissman , J. D. , Hatfleld , J. S. , Harkins , C. , Sloane , B. F. and Monn , K. V.Arrest and extravasation of B16 amelanotic melanoma in marine lungs . Lab. Invest. , 53 , 470 – 478 ( 1985. ). - PubMed
-
- Menter , D. G. , Hatfield , J. S. , Harkins , C. , Sloane , B. F. , Taylor , J. D. , Crissman , J. D. and Honn , K. V.Tumor cell‐platelet interaction in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells . Clin. Exp. Metastasis , 5 , 65 – 78 ( 1987. ). - PubMed
-
- Jones , D. S. , Wallare , A. C. and Frazer , Z. E.Sequence of events in experimental metastasis of Walker‐256 tumor: light, immunofluorescent and electron microscopic observations . J. Natl. Cancer Inst. , 46 , 493 – 504 ( 1971. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous